Close Menu

Glaucus Proteomics Has Closed Its Doors

Glaucus Proteomics ceased its operations in October and laid off 19 employees, after a failed financing round. The Netherlands-based company had “the ink wet on a financing round of $19.5 million,” when the fourth investor, an institutional bank, pulled out at closing, said Ian Humphery Smith, Glaucus’ founder and COO, adding that “the company died quickly.” Glaucus had been developing technologies to produce protein and antibody microarrays.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.